Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK1278863

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Daprodustat (GSK1278863) is a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor in development for treatment of… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
2017
2017
Decreased erythropoietin (EPO) production, shortened erythrocyte survival, and other factors reducing the response to EPO… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2016
Highly Cited
2016
Hypoxia-inducible factor prolyl hydroxylase inhibitors stabilize levels of hypoxia-inducible factor that upregulate transcription… Expand
  • figure 1
Highly Cited
2016
Highly Cited
2016
BACKGROUND Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2016
Highly Cited
2016
Background: Daprodustat (GSK1278863) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2016
2016
GSK1278863 is an investigative drug under investigation for treatment of anemia associated with chronic kidney disease. Its… Expand
2016
2016
Drug candidates, which have the potential of enhancing athletic performance represent a risk of being misused in elite sport… Expand
  • figure 1
  • figure 2
  • table 2
  • figure 3
2015
2015
This study was performed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of GSK1278863, a novel prolyl… Expand
2014
2014
Hypoxia inducible factor (HIF) stabilization by HIF-prolyl hydroxylase (PHD) inhibitors may improve ischemic conditions such as… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2014
2014
Anemia, a frequent complication of chronic kidney disease, is most commonly treated with recombinant human erythropoiesis… Expand